Deltex Medical Group PLC Annual Report and Notification of AGM (8056X)
02 May 2019 - 1:47AM
UK Regulatory
TIDMDEMG
RNS Number : 8056X
Deltex Medical Group PLC
01 May 2019
The following amendments have been made to the Annual report and
Announcement of AGM announcement released on 1 May 2019 at 15:16
under RNS number 7919X.
The related voting instruction card was posted on 29 April 2019
to shareholders on the register on 15 April 2019.
All other details remain unchanged.
The full amended text is shown below.
1 May 2019
Deltex Medical Group plc
("Deltex Medical" or "the Company")
Publication of Annual Report and Notification of Annual General
Meeting (AGM)
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), gives notice that its
Annual Report and Accounts for the year ended 31 December 2018
("Annual Report & Accounts 2018") has been published on the
"Annual & Interim Reports" section of the Company's website at
www.deltexmedical.com.
The Company announced a summary of its results on 25 April 2019
and posted printed copies of the Annual Report & Accounts 2018,
together with a personalised proxy card, on 26 April 2019 to
shareholders who have informed the Company of their wish to receive
reports of this nature in hard copy.
Deltex Medical also announces that its AGM will be held at
11:00am on 22 May 2019 at the offices of DAC Beachcroft LLP, 25
Walbrook, London EC4N 8AF. The formal notice and resolutions can be
found on pages 97 and 98 of the Annual Report & Accounts 2018.
The related voting instruction card was posted on 29 April 2019 to
shareholders on the register on 15 April 2019.
For further information, please contact: -
Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman investorinfo@deltexmedical.com
Andy Mears, Chief Executive
Jonathan Shaw, Group Finance Director
Nominated Adviser & Broker
Arden Partners plc 020 7614 5900
Ciaran Walsh
Dan Gee-Summons
Joint Broker
Turner Pope Investments (TPI)
Ltd 0203 621 4120
Andy Thacker info@turnerpope.com
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary oesophageal doppler
monitoring ("ODM") (TrueVue Doppler) measures blood flow velocity
in the central circulation in real time. Minimally invasive, easy
to set-up and quick to focus, the technology generates a
low-frequency ultrasound signal which is highly sensitive to
changes in blood flow and measures such changes in 'real time'.
Deltex Medical is the only company in the enhanced haemodynamic
space to have built a robust and credible evidence base
demonstrating both the clinical and economic benefits of its core
technology, TrueVue Doppler. This technology has been proven in a
wide range of clinical trials to reduce complications suffered by
patients after surgery and consequently save hospitals the costs of
treating those complications.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor
platform now provides clinicians with two further advanced
haemodynamic monitoring technologies. TrueVue Impedance is an
entirely non-invasive monitoring technology which transmits low
magnitude, high frequency electrical signals through the thorax and
measures the changes to this signal when the heart pumps blood.
TrueVue PressureWave uses the peripheral blood pressure signal
analysis to give doctors information on changes in the circulation
and is particularly suited to monitoring lower risk or
haemodynamically stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as an
important part of the anaesthesia protocol for surgical patients.
Consequently, the Group's focus is on maximising value from the
opportunities presented, as enhanced haemodynamic management is
adopted into routine clinical practice around the world. The Group
aims to provide clinicians with a single platform - a 'haemodynamic
workstation' - which offers them a range of technologies from
simple to sophisticated to be deployed according to the patient's
condition as well as the skill and expertise of the user. Doing
this will enable the Group to partner healthcare providers to
support modern haemodynamic management across the whole
hospital.
The Group is currently in the implementation phase of achieving
this goal in a number of territories worldwide, operating directly
in the UK and the USA, and through distribution arrangements in
approximately 40 other countries.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOAEFLFBKEFZBBE
(END) Dow Jones Newswires
May 01, 2019 11:47 ET (15:47 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024